|Rapid Review Complete
|Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.